tile page arthritic joint-targeting sirna encapsulated liposome:...
TRANSCRIPT
JPET #185884
1
Tile Page
Arthritic Joint-Targeting siRNA Encapsulated Liposome: Implication for Treatment
Strategy for Rheumatoid Arthritis
Yukiko Komano, Nobuhiro Yagi, Ikumi Onoue, Kayoko Kaneko, Nobuyuki Miyasaka and
Toshihiro Nanki
Department of Medicine and Rheumatology, Graduate School of Medical and Dental
Sciences, Tokyo Medical and Dental University, Tokyo, Japan (Y.K., I.O., K.K., N.M.,
T.N.); and Kyowa Hakko Kirin Co., Ltd, Shizuoka, Japan (N.Y.).
JPET Fast Forward. Published on October 12, 2011 as DOI:10.1124/jpet.111.185884
Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
2
Running title page
Running title: Treatment of Arthritis using siRNA-Encapsulated Liposome
The number of text pages; 11
The number of figures; 3
The number of references; 18
The number of words; Abstract, 240
Introduction, 334
Discussion, 785.
Abbreviations; siRNA: short interfering RNAs; RA: rheumatoid arthritis; WS: wrapsome;
TNF-α: tumor necrosis factor-α; CIA: collagen induced arthritis; RT-PCR: reverse
transcriptase-polymerase chain reaction; IL: interleukin; GAPDH:
glyceraldehyde-3-phosphate dehydrogenase; MFI: mean fluorescence intensity.
Recommended section assignments; Inflammation, Immunopharmacology, and Asthma.
Corresponding author:
Toshihiro Nanki, MD
Department of Medicine and Rheumatology, Graduate School of Medical and Dental
Sciences, Tokyo Medical and Dental University
1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519 Japan.
Tel: +81-3-5803-4677
Fax: +81-3-5803-4694
E-mail: [email protected]
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
3
Abstract
RNA interference, mediated by small interfering RNA (siRNA), is effective in silencing
genes with a high degree of specificity. To explore the therapeutic potential of systemically
administered siRNA for rheumatoid arthritis (RA), we tested the complex of siRNA and the
recently developed wrapsome (siRNA/WS), containing siRNA encapsulated liposome, in
mice with collagen-induced arthritis (CIA). Mice with CIA received intravenous injection of
Cy5-labeled siRNA/WS. Fluorescence stereoscopic microscopy and flow cytometry were
used to assess the siRNA/WS tissue distribution. The efficacy of siRNA targeting tumor
necrosis factor (TNF)-α/WS in CIA was evaluated by arthritis score. TNF-α mRNA levels in
the joints were measured by real-time reverse transcriptase-polymerase chain reaction. The
intensity of Cy5-fluorescence was higher in arthritic joints than in non-arthritic sites in
Cy5-siRNA/WS-treated mice, and remained higher up to 48 hrs post-injection, compared
with naked Cy5-siRNA-treated mice. Cy5-fluorescence intensity was higher in synovial cells
than splenocytes, bone marrow cells and peripheral blood leukocytes. The majority of
Cy5-positive synovial cells were CD11b+ with only a few CD3+ cells. Treatment with TNF-α
siRNA/WS resulted in significant decreases in severity of arthritis and TNF-α mRNA level in
the joints compared with control siRNA/WS. In conclusion, the use of our WS allowed
efficient and targeted delivery of siRNAs to arthritic joints. The siRNA/WS was mainly
incorporated into CD11b+ cells, including macrophages and neutrophils, in the inflamed
synovium, suggesting its potential therapeutic effects in RA by silencing the expression of
inflammatory molecules produced by these cells.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
4
Introduction
RNA interference (RNAi), mediated by small interfering RNA (siRNA), is a powerful
way to silence genes with a high degree of specificity, and potentially become a therapeutic
approach in various diseases including viral infections and proliferative vascular retinopathies
(de Fougerolles et al., 2007; Whitehead et al., 2009). To apply this technology to the
treatment of rheumatoid arthritis (RA), it is important to develop means to deliver siRNA via
systemic injection to multiple affected joints. The delivery tool should be stable, and protect
siRNA from nuclease attack in vivo. Our group used the wrapsome (WS) as a vehicle for
siRNA delivery, which was recently designed with a core composed of a cationic lipid
bilayer and siRNA complex enveloped in a neutral lipid bilayer with polyethylene glycol on
the surface (Yagi et al., 2009). In contrast to the widely used cationic liposomes, the WS is
unique in that it is uncharged. The cationic liposomes are prone to bind in vivo to plasma
proteins due to their cationic nature. Because the WS carries a neutral surface charge, the loss
of WS function by the plasma protein is less likely. For the same reason, the attachment of
WS to the endothelial cell membrane and its entrapment by the reticuloendothelial systems
are avoidable, which can otherwise lead to adverse effects, including embolism, a
complication reported with the use of cationic liposomes (Litzinger et al., 1996). In addition,
the surface pegylation of WS confers the long half life of WS in systemic circulation (t1/2 of
17.6 hr). Investigator in our group has recently demonstrated that the use of WS results in
accumulation of siRNA into tumors in vivo without any signs of significant toxicity (Yagi, et
al., 2009).
In the present study, we evaluated the accumulation of siRNA/WS complex into the
inflamed joints of mice with experimentally-induced arthritis. Also, the therapeutic potential
of the siRNA/WS complex targeting tumor necrosis factor (TNF)-α, which is produced
primarily by macrophages in the synovia of the affected joints, was assessed in the arthritic
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
5
mice.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
6
Materials and Methods
Preparation of siRNA Encapsulated Liposome. All siRNAs including fluorescence
labeled randomized-siRNA were synthesized and purified by Hokkaido System Science
(Hokkaido, Japan). The siRNA sequences were as follows: control randomized-siRNA sense
5’- GGU ACA CAU GUG CAC ACA CdTdT -3’ and antisense 5’- GUG UGU GCA CAU
GUG UAC CdTdT -3’; TNF-α-siRNA sense 5’- GUG CCU AUG UCU CAG CCU CdTdT
-3’ and antisense 5’- GAG GCU GAG ACA UAG GCA CdTdT -3’ (Schiffelers et al., 2005).
Preparation of the complex of siRNAs and WS, which was developed as delivery system for
siRNAs, was described previously (Yagi, et al., 2009). The siRNA/WS complex consists of
siRNA and cationic lipids enveloped by a neutral lipid bilayer containing Egg-phosphatidyl
choline, and is ~100 nm in diameter.
Imaging of siRNA/WS Accumulation in Arthritic Joints of Mice with
Collagen-Induced Arthritis (CIA). Murine CIA was induced in 8-week-old male DBA/1J
mice (Charles River Japan, Tokyo, Japan) by twice immunization with bovine type II
collagen (Collagen Research Center, Tokyo) and complete Freund’s adjuvant (Difco
laboratories, Detroit, MI) (Nanki et al., 2005). From the day of the second immunization (day
0), mice were examined for signs of joint inflammation. The severity of arthritis was
evaluated using the following clinical scoring method (Nanki, et al., 2005): score 0, normal; 1,
erythema and mild swelling confined to the mid-foot or ankle joint; 2, erythema and mild
swelling extending from the ankle to the mid-foot; 3, erythema and moderate swelling
extending from the ankle to the metatarsal joint; 4, erythema and severe swelling of the ankle,
foot, and digits. The clinical score was defined as the sum of the scores of all four paws of
each mouse. At day 7, CIA mice showing joint inflammation scored more than 2 in the above
definition at least in a paw, were randomly injected either with a single injection of
Cy5-labeled siRNA/WS, naked Cy5-labeled siRNA, or saline via the tail vein. Considering
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
7
the limited sensitivity for detection of fluorescence in vivo setting, dose of the Cy5-labeled
siRNA were selected to be 50 and 150 μg for whole-body imaging (Yagi, et al., 2009).
Cy5-fluorescence was monitored for up to 96 hrs after administration using fluorescence
stereoscopic microscope (Macro Imaging System, Nippon Roper, Tokyo). The level of
fluorescence labeled-siRNA in the affected joints was quantified by analyzing regions of
interest using image analysis software (Nippon Roper). Approval for the experimental
protocol was obtained from the Institutional Animal Care and Use Committee of Tokyo
Medical and Dental University.
Analysis of siRNA/WS Tissue Distribution in the CIA Mice. At day 7, CIA mice
showing joint inflammation as described above were randomly injected either with 50 μg of
Cy5-labeled siRNA/WS, naked Cy5-labeled siRNA, or saline via the tail vein. Based on the
results of the whole-body imaging, the dosage of Cy5-labeled siRNA/WS for this FACS
analysis was selected. Twenty-four hours later, tissues (synovium, spleen, and bone marrow)
were harvested and single cell suspensions were prepared using standard procedures.
Synovial tissues were harvested from arthritic joints (scored more than 2). Peripheral blood
leukocytes were isolated by depletion of red blood cells with NH4Cl hemolytic solution. The
cells were analyzed for Cy5-fluorescence using a FACSCalibur (BD Bioscience, San Jose,
CA). The following mAbs were used for staining: CD11b-phycoerythrin (eBioscience, San
Diego, CA), F4/80-fluorescein isothiocyanate (eBioscience), CD3-fluorescein isothiocyanate
(BD Pharmingen, Franklin Lakes, NJ), and CD19-phycoerythrin (eBioscience).
Analysis of the Effect of TNF-α-siRNA/WS in CIA Mice. At the day of the second
immunization (day 0), mice were grouped on the basis of equal average clinical scores, and
injected intravenously with TNF-α siRNA/WS, naked TNF-α siRNA, control
randomized-siRNA/WS (1 or 10 μg/day), or buffered saline three times per week until day 10.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
8
Clinical arthritis score and the incidence of arthritis were evaluated. In addition, thickness of
each paw was measured using calipers.
Real-Time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). CIA
mice were sacrificed on day 12, and paws were pulverized using cryopress (Microtec, Chiba,
Japan). Total RNA was prepared from 50 mg of the sample using a RNeasy RNA isolation
kit (Qiagen, Valencia, CA). The levels of TNF-α mRNA were measured by real-time
RT-PCR assay using TaqMan probes [TNF-α (Mm00443258) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Mm99999915) (Applied Biosystems,
Foster City, CA)]. Amplification was performed in a thermal cycler (ABI Prism 7000;
Applied Biosystems).
Statistical Analysis. Data are expressed as mean ± SEM. For comparing clinical
scores between groups, the non-paired Student’s t-test was used. For comparing incidence of
arthritis between groups, Fisher's exact test was used. Analysis were made using StatView
program (Abacus Concepts, Berkely, CA). P values <0.05 were considered significant.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
9
Results
Accumulation of Systemically Administered siRNA/WS in Arthritic Joints of
murine CIA. The potential of WS as a delivery tool of siRNA was investigated in CIA. At
day 7, when the CIA mice developed arthritis (scored more than 2 at least in a paw), they
were injected either with fluorescence (Cy5)-labeled siRNA/WS or naked Cy5-labeled
siRNA (50 or 150 μg). After 12 hrs, observation under stereoscopic microscope showed
accumulation of fluorescence in the arthritic joints but not in non-arthritic sites in mice
treated with Cy5-siRNA /WS (150 μg), and the levels of the accumulation appears higher in
severely swollen joints compared to less swollen or normal joints (Figures 1A and B).
Although the intensity was weaker, fluorescence was detected in arthritic joints in mice
treated with 50 μg of Cy5-siRNA/WS (data not shown). In mice treated with naked
Cy5-siRNA (150 μg), although a low level of fluorescence was observed in arthritic joints
immediately after the injection, the fluorescence disappeared within 12 hrs (Figure 1C). The
intensity of the fluorescence level remained high up to 48 hrs post-injection in the arthritic
joints of the mice treated with Cy5-siRNA/WS (Figure 1D). Although the intensity was
weaker, fluorescence was detected in arthritic joints in mice treated with 50 μg of
Cy5-siRNA/WS (data not shown). Contrary, the intensity of the fluorescence level in the
arthritic joints of the mice treated with naked Cy5-siRNA (150 μg) was much lower
compared to that in the mice treated with Cy5-siRNA/WS (Figure 1D).
Next, the tissue distribution of systemically administered Cy5-siRNA/WS was
examined in the CIA mice. At 24-hr post-injection of 50 μg of Cy5-siRNA/WS, naked
Cy5-siRNA or saline, the Cy5-fluorescence levels in cells from the synovium, spleen, bone
marrow and peripheral blood leukocytes were examined by flow cytometry. Compared to
saline injected mice, the fluorescence intensity of Cy5 was higher in cells harvested from the
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
10
synovium of naked Cy5-siRNA injected CIA mice (Figure 2A). Moreover, the Cy5 intensity
was significantly enhanced in synovial cells from mice injected with Cy5-siRNA/WS
compared to those with naked Cy5-siRNA, with the ratio of mean fluorescence intensity
(MFI) (Cy5-siRNA/WS vs. naked Cy5-siRNA) of 4.4 (Figure 2B). The Cy5 intensity in bone
marrow cells and peripheral blood leukocytes of naked Cy5-siRNA injected CIA mice was
also higher, however, the Cy5 intensity in mice injected with Cy5-siRNA/WS was not
enhanced (MFI ratios: 0.97 and 0.57, respectively). Of note, the MFI of Cy5 was much higher
in synovial cells from Cy5-siRNA/WS injected mice compared to bone marrow cells and
peripheral blood leukocytes (Figure 2B). On the other hand, the fluorescence intensity was
not significantly altered in splenocytes.
Next, we determined the cells that incorporate the Cy5-siRNA/WS in the synovium. At
24-hr post-injection, the synovial cells of mice treated with naked Cy5-siRNA or
Cy5-siRNA/WS were analyzed by flow cytometry after staining with anti-CD11b, -F4/80,
-CD3 or –CD19 mAb. In the Cy5-siRNA/WS injected mice, eighty-one percent of the
synovial cells were Cy5-positive, and most of the Cy5-positive cells (>75%) were CD11b+.
In addition, 92% of CD11b+ and 67% of F4/80+ cells were Cy5-positive, whereas, only 20%
of CD3+ cells were Cy5-positive. Although the majority of CD11b+ cells in the synovium of
naked Cy5-siRNA-treated mice was also Cy5-positive (82%), fewer F4/80+ and CD3+ cells
were Cy5-positive (1% and 10%, respectively) compared with Cy5-siRNA/WS-treated mice
(Figure 2C). CD11b+ synovial cells in CIA mainly consisted of macrophages (70%) and
secondary dominant neutrophils (30%) (data not shown). CD19 positive cells were very few
in the synovial cells (less than 0.1%).
These results suggest that both selective delivery and retention of Cy5-siRNA to
inflamed synovium could be achieved using WS as a carrier of the siRNA, and that
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
11
systemically administered siRNA/WS would efficiently target macrophages and neutrophils
in inflamed joints.
Efficacy of siRNA Targeting TNF-α/WS for CIA. Experimental evidence indicates
that functional blockade of TNF-α effectively inhibits CIA (Kim et al., 2002). Accordingly,
we analyzed the effect of systemic administration of siRNA/WS targeting TNF-α on CIA.
Mice treated with TNF-α siRNA/WS at 1 and 10 μg showed substantially decreased and
delayed incidence of arthritis over those treated with control siRNA/WS (P<0.05. TNF-α
siRNA/WS 10 μg v.s. control 10 μg, at day 7, Figure 3A). Treatment with 10 μg siRNA/WS
targeting TNF-α significantly lowered the disease severity expressed as clinical arthritis score
and paw thickness, compared with control siRNA/WS (Figures 3B and C). On the other hand,
naked TNF-α siRNA had no effect on CIA (data not shown). In addition, TNF-α mRNA
levels in the paws of TNF-α siRNA/WS (10 μg)-treated mice were significantly lower than
those treated with control siRNA/WS (Figure 3D). No signs of toxicity were observed both in
control siRNA/WS and TNF-α siRNA/WS treated mice. These results suggest that
down-regulation of TNF-α expression in the synovial tissue by systemically administered
TNF-α-targeting siRNA/WS inhibited CIA.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
12
Discussion
In this study, we showed that systemically administered siRNA/WS complex
accumulated in arthritic joint in murine CIA, where the complex was preferably incorporated
into CD11b+ macrophages and neutrophils. Moreover, treatment with siRNA/WS targeting
TNF-α ameliorated CIA.
RA is characterized by chronic synovitis affecting multiple joints, and synovial
macrophages play central roles in the pathogenesis by producing various proinflammatory
cytokines such as TNF-α, interleukin (IL)-1, and IL-6. Treatment with anti-TNF-α mAb was
effective for murine CIA (Williams et al., 1992). Moreover, TNF-α blockade was efficacious
in the treatment of RA (Smolen et al., 2007). However, systemic administration of TNF-α
inhibitor could impair immune system, which increases the development of infectious
diseases (Komano et al., 2011), including reactivation of latent infections such as tuberculosis
(Keane et al., 2001). Therefore, selective delivery of siRNA that targets macrophages in the
affected synovia at multiple anatomical sites is an ideal strategy. Our results demonstrated
that this goal can be achieved using the siRNA/WS formation, and such treatment might be
potentially useful for RA in human by inhibition of cytokine production by synovial
macrophages. Our method could also target other proinflammatory cytokines or intracellular
molecules in the synovial macrophages that are known to play some roles in chronic joint
inflammation (Mosser et al., 2008).
In arthritic synovium, incorporation of siRNA/WS was observed in majority of
CD11b+ cells and in more than half of the F4/80+ cells, whereas a few in the CD3+ cells.
CD11b+ synovial cells in our CIA model mainly consisted of macrophages and neutrophils. It
was reported that F4/80+ synovial cells were mature macrophages (Morris et al., 1991). The
mechanism of the selective incorporation of siRNA/WS in macrophages and neutrophils in
the inflamed synovium is not fully understood. It is unlikely that the selective siRNA delivery
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
13
by siRNA/WS complex depends simply on the innate phagocytic capability of the cells.
Investigator in our group reported that the complex was able to transduce therapeutic siRNA
selectively into cancer cells in mice in vivo (Yagi, et al., 2009). It is possible that the
siRNA/WS is preferentially delivered and enter the affected synovium based on increased
angiogenesis and vascular permeability in such inflammatory tissues. Indeed, the size of
siRNA/WS is designed to maximize enhanced permeability and retention effect (Hall et al.,
2007). In addition, we recently found that systemically injected siRNA/WS was accumulated
in 12-O-tetradecanoylphorbol-13-acetate treated skin area in a mouse model of skin
inflammation (Yagi N: unpublished observations). This data also indicates that the
siRNA/WS has nature of accumulating into the inflamed tissue, probably due to increase in
vascular permeability. Alternatively, activated macrophages and neutrophils in the inflamed
synovium may have enhanced siRNA/WS uptake activity. Further studies are needed to
examine these probabilities and to determine the mechanism of action of siRNA/WS. The
siRNA/WS system could be potentially applicable to other systemic diseases in which
macrophages play a central pathogenic role. Understanding the molecular mechanism of
inflammatory tissue-selective siRNA/WS delivery should help us further improve the
therapeutic effect of WS-mediated siRNA delivery.
There are only a few studies that reported the success of siRNA-based therapy for RA
in animal models (Inoue et al., 2005; Khoury et al., 2008; Khoury et al., 2006; Schiffelers, et
al., 2005). Khoury et al. reported that systemic administration of a cationic liposome carrying
siRNA directed against TNF-α or a cocktail of siRNAs directed against proinflammatory
cytokines, including IL-1, -6, and -18, was effective against CIA (Khoury, et al., 2008;
Khoury, et al., 2006). The cationic liposome used in the above studies, however, could
rapidly be distributed to reticuloendotherial systems due to the micron-sized diameter and
positive surface property. In contrast, siRNA/WS was designed to be nano-sized (100 nm in
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
14
diameter) and neutrally charged, resulting in its efficient distribution into peripheral inflamed
tissue (Yagi, et al., 2009). Indeed, we confirmed remarkable accumulation and cellular
incorporation of the siRNA encapsulated WS in inflamed synovium, thus, the relative
contribution of macrophages in the affected joints to the therapeutic effect of siRNA might be
higher in the WS than the previously reported cationic liposome.
Treatment with TNF-α siRNA/WS from day 0 (when clinical arthritis just started
developing) showed therapeutic effect in CIA. However, when we started the treatment from
day 7 (when the arthritis were established), the CIA was not suppressed (data not shown).
Combining siRNA/WS with specific targeting approach (e.g. surface modification of
liposome) may improve therapeutic efficacy of this system (Koning et al., 2006).
In conclusion, our results showed that the siRNA/WS system enabled efficient
delivery of siRNA to arthritic joints. The siRNA/WS were incorporated into CD11b+
macrophages and neutrophils in the inflamed synovium, suggesting that it could be a
therapeutic tool to silence the expression of various molecules associated with the
pathogenesis of RA produced by these cells.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
15
Acknowledgments
We are grateful to Aya Sato for the excellent technical support.
Authorship Contributions
Participated in research design: Komano, Miyasaka, Nanki.
Conducted experiments: Komano. Yagi, Onoue, Kaneko.
Contributed new reagents or analytic tools: Yagi
Performed data analysis: Komano.
Wrote or contributed to the writing of the manuscript: Komano, Miyasaka, Nanki.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
16
References
de Fougerolles A, Vornlocher HP, Maraganore J, and Lieberman J (2007) Interfering with
disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov
6:443-453.
Hall JB, Dobrovolskaia MA, Patri AK, and McNeil SE (2007) Characterization of
nanoparticles for therapeutics. Nanomedicine (Lond) 2:789-803.
Inoue A, Takahashi KA, Mazda O, Terauchi R, Arai Y, Kishida T, Shin-Ya M, Asada H,
Morihara T, Tonomura H, Ohashi S, Kajikawa Y, Kawahito Y, Imanishi J, Kawata M,
and Kubo T (2005) Electro-transfer of small interfering RNA ameliorated arthritis in
rats. Biochem Biophys Res Commun 336:903-908.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN,
and Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis
factor alpha-neutralizing agent. N Engl J Med 345:1098-1104.
Khoury M, Escriou V, Courties G, Galy A, Yao R, Largeau C, Scherman D, Jorgensen C, and
Apparailly F (2008) Efficient suppression of murine arthritis by combined
anticytokine small interfering RNA lipoplexes. Arthritis Rheum 58:2356-2367.
Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C, Scherman D, Jorgensen
C, and Apparailly F (2006) Efficient new cationic liposome formulation for systemic
delivery of small interfering RNA silencing tumor necrosis factor alpha in
experimental arthritis. Arthritis Rheum 54:1867-1877.
Kim SH, Lechman ER, Kim S, Nash J, Oligino TJ, and Robbins PD (2002) Ex vivo gene
delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic
effect in antigen-induced arthritis. Mol Ther 6:591-600.
Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno
M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A,
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
17
Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, and Harigai
M (2011) Incidence and risk factors for serious infection in patients with rheumatoid
arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of
Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol
38:1258-1264.
Koning GA, Schiffelers RM, Wauben MH, Kok RJ, Mastrobattista E, Molema G, ten Hagen
TL, and Storm G (2006) Targeting of angiogenic endothelial cells at sites of
inflammation by dexamethasone phosphate-containing RGD peptide liposomes
inhibits experimental arthritis. Arthritis Rheum 54:1198-1208.
Litzinger DC, Brown JM, Wala I, Kaufman SA, Van GY, Farrell CL, and Collins D (1996)
Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim
Biophys Acta 1281:139-149.
Morris L, Graham CF, and Gordon S (1991) Macrophages in haemopoietic and other tissues
of the developing mouse detected by the monoclonal antibody F4/80. Development
112:517-526.
Mosser DM, and Edwards JP (2008) Exploring the full spectrum of macrophage activation.
Nat Rev Immunol 8:958-969.
Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, and Miyasaka N (2005)
Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis
Rheum 52:3004-3014.
Schiffelers RM, Xu J, Storm G, Woodle MC, and Scaria PV (2005) Effects of treatment with
small interfering RNA on joint inflammation in mice with collagen-induced arthritis.
Arthritis Rheum 52:1314-1318.
Smolen JS, Aletaha D, Koeller M, Weisman MH, and Emery P (2007) New therapies for
treatment of rheumatoid arthritis. Lancet 370:1861-1874.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
18
Whitehead KA, Langer R, and Anderson DG (2009) Knocking down barriers: advances in
siRNA delivery. Nat Rev Drug Discov 8:129-138.
Williams RO, Feldmann M, and Maini RN (1992) Anti-tumor necrosis factor ameliorates
joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A
89:9784-9788.
Yagi N, Manabe I, Tottori T, Ishihara A, Ogata F, Kim JH, Nishimura S, Fujiu K, Oishi Y,
Itaka K, Kato Y, Yamauchi M, and Nagai R (2009) A nanoparticle system specifically
designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res
69:6531-6538.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
19
Footnotes
This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry
of Health, Labor and Welfare, the Ministry of Education, Culture, Sports, Science, and
Technology, Japan, and the Japanese Ministry of Education, Global Center of Excellence
(GCOE) Program, International Research Center for Molecular Science in Tooth and Bone
Diseases.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
20
Legends for Figures
Figure 1. Accumulation of systemically administered siRNA/WS in arthritic sites
At day 7 after induction of CIA, mice with arthritis (scored more than 2 at least in a paw)
were injected with saline, naked Cy5-siRNA or Cy5-siRNA/WS. A, mice were examined 12
hrs later for accumulation of the Cy5-fluorescence by stereoscopic microscope. The arrows
indicate the sites where the fluorescence was observed. B, Arabic numerals on each paw
indicate arthritis score (top), and arrows show the accumulation of the fluorescence observed
in the corresponding paws (bottom). C, Fluorescence observed in arthritic hind paws of mice
injected either with naked Cy5-siRNA(150 μg /body) or Cy5-siRNA/WS (150 μg /body) at 0
min (immediately after the injection) and 12 hrs. D, Time course of the fluorescence intensity
in arthritic hind paws (arthritis score =3) of mice injected with naked Cy5-siRNA (150 μg
/body) or Cy5-siRNA/WS (150 μg /body). Data are mean ± SEM, n=3. A-C, Representative
photographs of 8 mice are shown.
Figure 2. Tissue distributions of systemically administered siRNA/WS
At day 7 after induction of CIA, mice with arthritis (scored more than 2 at least in a paw)
were injected with saline, naked Cy5-siRNA or Cy5-siRNA/WS. A, Twelve hrs after the
injection, the levels of Cy5-fluorescence in cells extracted from the synovium, spleen, bone
marrow and peripheral blood leukocytes were analyzed by flow cytometry. B, Mean
fluorescence intensity (MFI) of Cy5 in the tissues. RFU, relative fluorescence unit. C,
Synovial cells from the mice injected with naked Cy5-siRNA or Cy5-siRNA/WS were
stained with anti-CD11b, -F4/80, or -CD3 mAb, and Cy5 expression in CD11b+, F4/80+, or
CD3+ cells was analyzed by flow cytometry. The percentage of Cy5-positive cells was
determined for each cell type. n=2-3 for each condition (A-C). Synovial cells from the three
mice were analyzed altogether (A-C).
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET #185884
21
Figure 3. Effects of systemic administration of siRNA targeting TNF-α/WS on CIA
A-C, TNF-α siRNA/WS (1 or 10 μg) or control siRNA/WS (10 μg) was injected
intravenously in CIA mice three times per week starting from the day of the second
immunization (day 0) to day 10. The incidence of arthritis (A), arthritis score (B), and paw
thickness (C) were evaluated continuously until day 10. D, At day 12, TNF-α mRNA
expression in the paw was analyzed by real-time RT-PCR. Data are mean ± SEM of 5-13
mice in each group. *P<0.05 mice treated with TNF-α siRNA/WS 10 μg v.s. control
siRNA/WS. ■; control siRNA/WS 10 μg/body, △; TNF-α siRNA/WS 1 μg/body, ●; TNF-α
siRNA/WS 10 μg/body, ◆; normal
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on October 12, 2011 as DOI: 10.1124/jpet.111.185884
at ASPE
T Journals on M
ay 11, 2020jpet.aspetjournals.org
Dow
nloaded from
0
10000
20000
30000
40000
A C
0 3
1 3
2 0
3 1
B
3 2 32
0 hr
12 hrs
Naked Cy5-siRNA150 μg
Cy5-siRNA/WL150 μg
Fluorescenceimage
Photograph
Cy5-siRNA/WL (150 μg) injected mice
Cy5-siRNA/WL (150 μg) injected mice
Fluorescence image of arthritic hind paws
D
Figure 1
12 24 48 72 960relative fluorescence intensity
(hrs)
post-injection
⃟ naked Cy5-siRNA
■ Cy5-siRNA/WS
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on O
ctober 12, 2011 as DO
I: 10.1124/jpet.111.185884 at ASPET Journals on May 11, 2020 jpet.aspetjournals.org Downloaded from
spleen
peripheral blood
leukocyte
synovium
bone marrow
Cy5 fluorescence
A
C
0 200 400 600 800
peripheral W BC
bone m arrow
spleen
synovium
B
0 200 400 600 800
MFI (RFU)
spleen
synovium
bone marrow
saline
naked Cy5-siRNA
Cy5-siRNA/WS
peripheral blood
leukocyte
Figure 2
20
40
60
80
0Cy-5 positive cells
%100
□ naked Cy5-siRNA-treated mice
■ Cy5-siRNA/WS-treated mice
CD11b+ F4/80+ CD3+
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on O
ctober 12, 2011 as DO
I: 10.1124/jpet.111.185884 at ASPET Journals on May 11, 2020 jpet.aspetjournals.org Downloaded from
incid
ence o
f art
hritis (
%)
0
20
40
60
80
100
0 3 5 7 10
0
2
4
6
8
0 3 5 7 10
art
hritis s
core
A C
days after the second immunization
days after the second immunization
**
*
B
-2.22E-16
0.2
0.4
0.6
0.8
1
1.2
control siRNA/WS TNF-α siRNA/WSrela
tive tra
nscript le
vel
0
*
Figure 3
1.5
2
2.5
3
1 2 3 4thic
kness o
f paw
s (
mm
)
D
0 5 7 10
days after the second immunization
**
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on O
ctober 12, 2011 as DO
I: 10.1124/jpet.111.185884 at ASPET Journals on May 11, 2020 jpet.aspetjournals.org Downloaded from